Dr. Claus Møller has been a significant player in the pharmaceutical industry. He earned a Ph.D. in Pharmaceutical Sciences from the University of Copenhagen and served as the CEO of Y-mAbs Therapeutics, Inc., showcasing his expertise in biotech. During his...

Dr. Claus Møller has been a significant player in the pharmaceutical industry. He earned a Ph.D. in Pharmaceutical Sciences from the University of Copenhagen and served as the CEO of Y-mAbs Therapeutics, Inc., showcasing his expertise in biotech. During his time, Y-mAbs focused on innovative treatments, particularly in oncology. Notably, Dr. Møller stepped down from his role in April 2022, leaving behind a legacy of leadership. His total compensation in his final year included significant severance payments, which highlighted the company's appreciation for his contributions. He had a successful track record that included a move into higher responsibilities quickly after joining the company. His experience and decisions undoubtedly influenced the direction of Y-mAbs, which is known for its emphasis on long-term performance and innovation in treatments. Dr. Møller's journey reflects a commitment to both science and the business side of pharmaceuticals, making him a noteworthy figure in the industry.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Y-mAbs Therapeutics, Inc. CEOs

Y

Dr. Claus Møller

Ex-CEO of Y-mAbs Therapeutics, Inc.

Education

Ph.D. in Pharmaceutical Sciences from the University of Copenhagen

Sector of Economy

Healthcare

Born

January 1, 1971 - 54 years ago

CEO of Y-mAbs Therapeutics, Inc. for

6 years 1 month (Mar 2016 - Apr 2022)

Previous Experience

Formerly held positions at various pharmaceutical companies including Novo Nordisk and Amgen.

Rivals

Competitors/colleagues of Dr. Claus Møller

Holdings

See how much did Dr. Claus Møller make over time.

During his tenure at Y-mAbs Therapeutics, Dr. Claus Møller held a significant amount of stock options. By 2021, he had options for 500,000 shares at an exercise price of $2.00 and another 275,000 shares at $30.34. However, after stepping down...

During his tenure at Y-mAbs Therapeutics, Dr. Claus Møller held a significant amount of stock options. By 2021, he had options for 500,000 shares at an exercise price of $2.00 and another 275,000 shares at $30.34. However, after stepping down in April 2022, the value of his holdings started to fluctuate. In 2021, Dr. Møller's potential wealth was quite high due to these stock options, reflecting confidence in the company's future. His holdings were closely tied to the performance of Y-mAbs, which focuses heavily on innovative cancer therapies. While he exited Y-mAbs amidst changes in leadership, the worth of these options depended on the company's stock market performance moving forward. Dr. Møller's financial interests remained engaged with the growth of the company long after his departure.

Total Stock Sold

$9.87M

YMAB

$9.87M

250,000 YMAB shares

What if they kept their stock?

If Dr. Claus Møller didn't sell their stock, today they would have:
Extra YMAB250,000 shares worth $6.96M.
This is -29.49% and $2.91M less than what they got when they sold the stock.

Insider Trading

See recent insider trades of Dr. Claus Møller.

YMAB

$2.56M

YMAB at $51.12/share

Dec 2, 2020

Sale

YMAB

$7.38M

YMAB at $36.89/share

May 13, 2020

Sale

YMAB

$32.71K

YMAB at $17.22/share

Mar 17, 2020

Purchase

Compensation History

See how much did Dr. Claus Møller make over time.

In 2022, Dr. Claus Møller's total compensation reached approximately $1.2 million, largely due to severance payments and other benefits. This included a monthly housing allowance and accident insurance premiums. While he didn’t earn performance-based bonuses in his last year, his prior years showed substantial earnings, with 2021 notably seeing his compensation peak at over $3.2 million, driven by a mix of salary, stock options, and bonuses. His pay reflected the importance of high-level leadership in biopharma, balancing salary with performance metrics in previous years, even though 2022 marked a transition in his career. Overall, his compensation structure reveals how companies in the pharmaceutical sector often tie CEO earnings to long-term performance outcomes and market success.

Year

2022

Total Compensation

$1.21M

Salary

$283.04K

Board Justification

The compensation philosophy aims to attract and retain top executive talent while aligning compensation with company performance and market benchmarks.

Bonus

$0.00

Board Justification

Dr. Møller did not receive a performance-based cash bonus for 2022 given his departure in April 2022.

Other

$924.54K

Board Justification

Includes severance payments and benefits, a monthly housing allowance, telephone expenses, and accident insurance premiums.

Restricted Stock

$0.00(0 N/A)

Board Justification

No stock was vested in 2022 as Dr. Møller's existing equity awards which have been granted but not vested as of the Effective Date will vest in accordance with the standard vesting schedule consistent with a termination without cause.

Performance Metrics

Performance metrics for the CEO's compensation were not applicable for 2022 due to his departure.

Other Y-mAbs Therapeutics, Inc. CEOs

Here are other CEOs of Y-mAbs Therapeutics, Inc.

Thomas Gad

Founder and Ex-CEO of Y-mAbs Therapeutics, Inc.

April 2022 - November 2023